Paz-Ares L, Borghaei H, Liu SV, Peters S, et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet 2025 May 30:S0140-6736(25)01011-6. doi: 10.1016/S0140-6736(25)01011.
PMID: 40473449